Health Care • Biotechnology: Pharmaceutical Preparations
$68.35 ▼ -0.31
(-0.45%)
MKT CAP: $224.8M • VOL: 33.5K
52W L $29 52W H $98
SLGL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $19.4M | $11.5M | $1.6M |
| YoY Revenue Growth % | +68.0% | +642.5% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.5M | -$12.0M | -$29.3M |
| Operating Margin % | -38.9% | -80.0% | -80.0% |
| Net Income (GAAP) | -$6.1M | -$10.6M | -$27.2M |
| EBITDA (Normalized) | -$7.5M | -$12.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $322.0K | -$13.9M | -$17.7M |
| Capital Expenditures (CapEx) | $47.0K | $2.0K | — |
| Free Cash Flow (FCF) | $275.0K | -$13.9M | -$17.7M |
| FCF Margin % | 1.4% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $11.0M | $19.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $22.8M | $28.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SLGL.